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Abstract
OBJECTIVE: To explore the plasma metabolite pro-
files in patients with the syndrome of phlegm and
blood stasis in hyperlipidemia and atherosclerosis
(As), and to search for the metabolic biomarkers of
the syndrome.
METHODS: The plasma metabolite profiles of 31
patients with the syndrome of phlegm and blood
stasis in hyperlipidemia and As, 6 patients with syn-
dromes without phlegm and blood stasis, and 10
healthy subjects were analyzed by gas chromatog-
raphy-mass spectrometry (GC-MS). Partial least
squares-discriminant analyses (PLS-DA) were used
to carry out the pattern-recognition analyses of the
data. The plasma metabolic biomarkers of patients
were obtained by variable importance plot value
(VIP value) and Student's t-test. The structures of
biomarkers were defined by the National Institute
of Standards and Technology (NIST) database.
RESULTS: PLS-DA score plots of plasma metabo-
lomes did not show overlap between the
phlegm-blood stasis syndrome group and syn-
dromes without phlegm and blood stasis group,
whereas significant differences in the concentra-
tions in the plasma of 5 metabolites were found (P<
0.05). They were identified as urine, isoleucine, gluc-
uronic acid, palmitic acid and glycerol by searching
in NIST database. The concentrations of four metab-
olites in the plasma of patients with syndrome of
phlegm and blood stasis were higher than those
with syndromes without phlegm and blood stasis,
whereas the glycerol concentration was lower.
CONCLUSION: Compared with patients with syn-
dromes without phlegm and blood stasis, five me-
tabolites showed abnormal levels in patients with
the syndrome of phlegm and blood stasis. These
metabolites could be diagnostic and prognostic
biomarkers.
© 2012 JTCM. All rights reserved.
Keywords:Hyperlipidemias;Atherosclerosis; Metab-
olism; Biological markers; Phlegm and blood stasis
INTRODUCTION
Metabolomics is the study of temporal and spatial
changes of small-molecule metabolites after an organ-
ism is stimulated or disturbed. 1 From the viewpoint of
systems biology, a "syndrome" in Traditional Chinese
Medicine (TCM) might be a specific deviated state af-
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ter "disturbances" made to protein networks and gene
regulatory networks. Endogenous substances secreted
into blood and the uterine system have been shown to
be a group that contribute to TCM syndrome. Metabo-
lomics is able to solve these kind of problems. 2 On the
basis of the pattern of the association of syndrome and
disease, by using a metabolomic approach and compu-
tational mathematics, we explored the metabolic mark-
er group for the phlegm-blood stasis syndrome of hy-
perlipemia and atherosclerosis (As). We also identified
the endogenous substances contributing to the syn-
drome, and provided a basis and guidance for criteria
and treatment for the phlegm and blood stasis syn-
drome of hyperlipemia and As.
MATERIALS ANDMETHODS
Diagnostic criteria
The diagnostic criteria for hyperlipemia3 and As4
were as described previously. The diagnostic criteria
for TCM syndromes were: phlegm syndrome5, blood
stasis syndrome,6,7 syndrome of phlegm-blood stasis,8
syndrome of spleen-Qi deficiency,9 and syndrome of
kidney-Qi deficiency, liver-Qi stagnation or heart-Qi
deficiency.6 The inclusion criteria were: patients with
the diagnostic criteria described above set forth by
Western Medicine and with phlegm-blood stasis syn-
drome and syndromes without phlegm and blood sta-
sis prescribed by TCM. The exclusion criteria were
patients: 1) who did not fit the TCM diagnosis; 2)
with nephrotic syndrome, kidney and liver disease,
diabetes mellitus, endocrine disorder and hematopoi-
etic system disease; 3) with acute myocardial infarc-
tion, severe accidental damage, or major surgery to
cerebral vessels in the previous 6 months; 4) who
had been administered drugs for lipid regulation, pro-
motion of blood circulation or anti-As, or for other
diseases; 5) at pregnancy and lactation; 6) with hyper-
lipemia induced by drugs.
Clinical materials
Most of the patients in the present study had visited
the Cardiology Department of Dongzhimen Hospital
(affiliated to the Beijing University of Chinese Medi-
cine, Beijing, China) for the treatment of hyperlipemia
and As. We recruited 37 patients: 31 cases of phlegm-
blood stasis syndrome and 6 of syndromes without
phlegm and blood stasis. We also recruited a further 10
healthy subjects as the control group. Patients volun-
tarily signed the informed consent form. Patients in
the two groups and healthy subjects were comparable
with respect to sex and age (both P>0.05). Two millili-
ters of blood anticoagulated with ethylenediamine tet-
ra-acetic acid (EDTA) was extracted from the cubital
vein of each subject. Blood was centrifuged (3500 rpm
for 15 min at room temperature); the upper portion
(plasma) of the blood was transferred to an Eppendorf
tube and stored at -80°C.
Reagents and Instruments
Acetonitrile (chromatographically pure; Sinopharm
Chemical Reagent, Beijing, China), pyridine (chro-
matographic grade, Tianjin Dingguang Institute of
Fine Chemicals, Tianjin, China), margaric acid (Sig-
ma-Aldrich, St. Louis, MO, USA), methoxamine (Sig-
ma-Aldrich), N-Methyl-N- (trimethylsilyl) trifluoro-
acetamide (MSTFA) (Sigma-Aldrich), trimethylchlo-
rosilane (TMCS) (chromatographically pure, Sigma-Al-
drich) and normal heptane (analytically pure, Sino-
pharm Chemical Reagent) were purchased. A QP2010
gas chromatography-mass spectrometry (GC-MS)
from Shimadzu (Tokyo, Japan) was employed.
Plasma metabolomic detection
Plasma was removed from storage at -80°C and defrost-
ed. One-hundred microliters of plasma was transferred
to a centrifuge tube, 20 μL of margaric acid (1 mg/
mL) was added to the tube as the internal standard,
and 900 μL of methanol and water (9∶1) added to the
solution. The solution was vortex-mixed for 30 s, ultra-
sonicated in an ultrasonic ice bath for 10 min, and
then centrifuged (15 000 rpm, 15 min, 4°C). Superna-
tant (200 μL) was transferred and evaporated to dry-
ness in a vacuum. Then, 30 μL (15 mg/mL) of me-
thoxypyridine was added to the dried supernatant, and
the solution stored at room temperature for 16 h. One
hour after MSTFA (99∶1 TMCS, v/v) had been add-
ed, 200 μL of normal heptane was added to the solu-
tion. The solution was vortex-mixed for 30 s, and then
10 μL of supernatant transferred as an injection to be
used in GC-MS analyses. The same sample was used
for six continuous injections, and the relative standard
deviation (RSD) of each relative peak area computed
to reflect inter-assay accuracy.
GC-MS conditions
The temperature was maintained at 100°C for 3 min,
increased to 300°C at 8°C/min, then maintained for
2 min; the injection volume was 1.0 μL and the
split ratio 10∶1. The temperature at the injection
port was 280°C, the temperature at the interface was
250°C, and the ion source temperature was 200°C.
High-purity helium was used as the carrier gas at flow
rate of 1.0 mL/min. Electron impact ionization was ad-
opted with an electron energy of 70 eV and scanning
range of 35-800 m/z.
Statistical analyses
Common peaks (peaks common to each chromato-
gram) were selected according to the retention time of
each peak in the GC-MS total ion chromatograms.
Each peak area and internal standard peak area was
then calculated, and the metabolite concentration rep-
resented by the relative peak area (ratio of each peak ar-
ea to internal standard peak area). Partial least square
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(PLS) analyses were undertaken using SIMCA-2P
ver11.5. Differences in metabolite concentrations were
analyzed using Student's t-test (SPSS ver13. 0, Chica-
go, IL, USA).
RESULTS
Total ion chromatograms (TICs) of metabolomes in
each group
The same sample had six continuous injections, and
the RSD of relative peak area of each peak ranged be-
tween 2.05% and 6.75%. GC-MS TICs of plasma me-
tabolites in each group are shown in Figure 1. The Shi-
madzu Chromatographic Station found that each TIC
contained several substances, which were identified to
be 73 chemicals by the spectral library of the National
Institute of Standards and Technology (NIST; Beijing,
China). These 73 substances included amino acids (e.
g., alanine, glycine, valine, pyroglutamic acid) carbohy-
drates (e.g., galactose mannose) fatty acids (e.g., palmit-
ic acid linoleic acid) and other small-molecule metabo-
lites (e.g., urea, phosphoric acid).
Discrimination between groups
By carrying out partial least squares-discriminant analy-
ses (PLS-DA) for the 73 metabolites in plasma, all
groups were discriminated from each other (Figure 2).
Figure 2A, with each dot representing one specimen,
demonstrated all specimens to be scattered in the two
areas within the oval scatter plot. There was no overlap
between the hyperlipemia and As group and control
group, indicating that plasma metabolites could be
Figure 1 GC-MS TICs of plasma metabolomes in each group
A: healthy control group; B: phlegm-blood stasis syndrome group; C: syndromes without phlegm and blood stasis group.
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used to discriminate the control group from patients
with metabolic disorders. Similarly, Figure 2B did not
show overlap between the phlegm-blood stasis syn-
drome group and syndromes without phlegm and
blood stasis group. This finding indicated that plasma
metabolites could be used to discriminate the
phlegm-blood stasis syndrome group from syndromes
without phlegm and blood stasis group. The difference
was greater between the syndrome groups and control
group than that between the two syndrome groups.
Figure 3 PLS-DA loading plots of the phlegm-blood stasis syndrome group and syndromes without phlegm and blood stasis
group
PLS-DA: partial least squares-discriminant analyses.
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Figure 2 PLS-DA score plots of plasma metabolomes in each group
PLS-DA: partial least squares-discriminant analyses; A: control group and hyperlipemia and As group. (●) control group; (■) hy-
perlipemia and As. B: Phlegm-blood stasis syndrome group and syndromes without phlegm and blood stasis group. (●)
phlegm-blood stasis syndrome group; (■) syndromes without phlegm and blood stasis group.
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Endogenous metabolites
Urea
Isoleucine
Glucuronic acid
Palmitic acid
Glycerol
Control group
1.519±0.714
0.110±0.064
0.055±0.020
0.185±0.103
0.016±0.009
Syndromes without phlegm and
blood stasis group
1.220±0.344
0.008±0.005a
0.015±0.008a
0.102±0.017a
0.190±0.060b
Phlegm-blood stasis
syndrome group
1.814±0.332
0.069±0.037ac
0.040±0.015ac
0.134±0.076
0.082±0.043ac
Table 1 Comparison of plasma metabolite concentrations in the control group and different syndrome groups ( xˉ ±s)
Note: Compared with the control group, aP<0.05 and bP<0.01; Compared with the syndromes without phlegm and blood stasis
group, cP<0.05.
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This finding suggested that the model we established
was reasonable.
Furthermore, the metabolites that contributed to the
differences mentioned above were identified (Figure 3).
A PLS-DA loading plot ranked the 73 metabolites ac-
cording to their contribution to grouping. We then cal-
culated the VIP value of metabolites in the model, and
found 15 metabolites to have a VIP value >1. Student's
t-test demonstrated that, of the 15 metabolites, 5 me-
tabolites had different concentrations between groups
(P<0.05). The NIST spectral library search identified
the 5 metabolites to be urea, isoleucine, glucuronic ac-
id, palmitic acid and glycerol. The glycerol concentra-
tion in plasma in the phlegm-blood stasis syndrome
group was significantly less than in the syndromes with-
out phlegm and blood stasis group, and the concentra-
tions of the other 4 metabolites in the phlegm-blood
stasis syndrome group were significantly higher than in
the syndromes without phlegm and blood stasis group
(Table 1). These 5 metabolites could be important met-
abolic markers in plasma that can be used to discrimi-
nate between the two syndromes.
DISCUSSION
TCM categorizes hyperlipidemia into phlegm syn-
drome and blood stasis. Lipids and lipoprotein meta-
bolic disorders are believed to contribute to phlegm in
blood,10 whereas platelet activation, thrombosis, endo-
thelial injury and atheromatous plaques are thought to
be caused by blood stasis.11,12 On the basis of TCM the-
ory, clinical practice and many studies, we believe that,
as an important pathogenic factor to many diseases,
phlegm is the upstream cause of stasis, toxins, vessel in-
jury, and phlegm-blood stasis. Small-molecule sub-
stances such as inflammatory factors and free radicals
might have a role in the interaction between phlegm,
stasis and toxins. Phlegm-blood stasis is pathological
feature of the late phase of several chronic diseases,13
and phlegm-blood stasis syndrome is the major syn-
drome type in hyperlipidemia and As.14
By utilizing gas chromatography/time of flight-mass
spectrometry (GC/TOF-MS), we investigated the plas-
ma metabolomes in the control group, phlegm-blood
stasis syndrome group and syndromes without phlegm
and blood stasis group. Not only could syndrome
groups be discriminated from the control group, but
the two syndrome groups could be typed well from
each other. This finding indicated that small-molecule
endogenous chemicals (the study subjects of metabolo-
mics) could be utilized for discriminating between
TCM syndromes. Significant differences between the
groups were noted with regard to the concentrations of
endogenous metabolites. This finding suggested that
patients with hyperlipemia and As had changes in the
relevant biological metabolite pathways, and that the
two syndrome groups also had different metabolic
pathways.
Our previous study revealed that 9 metabolic markers
in patients with hyperlipemia and As were involved in
lipid metabolism, oxidative stress, energy metabolism,
and glycol-metabolic pathways, indicating that hyperli-
pemia and As are relevant to changes in several function-
al systems.15 The findings of the present study demon-
strated that the concentrations of urea, isoleucine, gluc-
uronic acid, and palmitic acid increased, and that the
concentration of glycerol decreased. Hence, these com-
pounds were specific markers helping to discriminate
phlegm-blood stasis syndrome and syndromes without
phlegm and blood stasis in hyperlipidemia and As.
Plasma urea concentration in the phlegm-blood stasis
syndrome group was higher than that in the syndromes
without phlegm and blood stasis group and control
group. This increase in urea concentration indicated
the increase in the concentration of nitrogen metabo-
lites, which are toxic and produced during the catabo-
lism of proteins and amino acids. The increase in urea
concentration suggested a metabolic disorder of pro-
teins and amino acids in patients with phlegm-blood
stasis syndrome.16
Isoleucine is a branched-chain amino acid that partici-
pates in glutamine generation. Isoleucine concentra-
tions in the two syndrome groups were less than those
in the control group, indicating worsened injury to cell
membranes, decreased immunity, and more damage to
the body by free radicals.17 Furthermore, isoleucine par-
ticipates in the energy supply during long-term contin-
uous energy consumption. Isoleucine concentrations in
the phlegm-blood stasis syndrome group were higher
than in the syndromes without phlegm and blood sta-
sis group and control group. This may be because: 1)
further liver damage in the phlegm-blood stasis syn-
drome group led to a decreased capacity of absorption
and endogenous proteins reserved for energy supply,
and 2) necrocytosis and cell rupture caused liver cells
to release amino acids into the blood. These two phe-
nomena would result in higher concentrations of ami-
no acids in blood.18,19
Glucuronic acid is relevant to glycometabolism in vivo,
and glucuronic acid concentration in two syndrome
group was different, indicating that the two syndromes
had different glycometabolism.20
The concentrations of palmitic acid in the two syn-
drome groups were less than those in the control
group, and this might be because decreased synthesis of
lipoproteins in hepatic tissue affected the secretion and
transport of lipids. Plasmic acid concentrations in the
phlegm-blood stasis syndrome group were higher than
in the syndromes without phlegm and blood stasis
group and control group, and this finding might be as-
sociated with a higher blood fat level in the phlegm-
blood stasis syndrome group.
Glycerol concentrations in the plasma of the two syn-
drome groups were higher than those in the control
group. This result might have been caused by higher
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blood fat levels in patients with hyperlipidemia and As.
Plasma glycerol concentrations in the phlegm-blood
stasis syndrome group were lower than those in the syn-
dromes without phlegm and blood stasis group. This
finding indicated that the two syndromes had different
glycolipid metabolism, to which glycerol is very rele-
vant.21
The present study revealed a specific marker group
for phlegm-blood stasis syndrome in hyperlipidemia
and As. This finding could provide a metabolomic
basis for endogenous substances and the treatment
of phlegm-blood stasis syndrome in hyperlipidemia
and As.22
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